TRIP12: A Potential Drug Target and Biomarker for Umbilical Cord Creatinine and Renal Function

Target Name: TRIP12

NCBI ID: G9320

TRIP12: A Potential Drug Target and Biomarker for Umbilical Cord Creatinine and Renal Function

The production of urine is a fundamental physiological function that occurs in all mammals. The ability of the kidney to remove waste products from the blood is a critical aspect of overall health and wellbeing. One of the critical waste products that the kidney removes is umbilical cord creatinine, which is the byproduct of muscle metabolism. Umbilical cord creatinine is harmful to the kidneys and has been associated with a number of health problems, including nephrotoxicity, impaired renal function, and even acute renal failure.

TRIP12 is a ubiquitin-protein ligase that is expressed in the kidney. It is involved in the regulation of a wide range of cellular processes, including cell survival, metabolism, and inflammation. In recent years, researchers have become increasingly interested in TRIP12 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and chronic kidney disease.

Drug Target Potential

TRIP12 has been shown to play a role in a number of cellular processes that are important for human health. One of its key functions is to regulate the levels of protein in the body, which is critical for maintaining cellular stability and preventing the formation of harmful aggregates that can cause diseases. In addition, TRIP12 is involved in the regulation of cell growth and metabolism, which are important for the development and maintenance of tissues and organs.

TRIP12 has also been shown to play a role in the regulation of inflammation. It is a well-known fact that inflammation is a major contributor to a wide range of diseases, including cancer, neurodegenerative diseases, and chronic kidney disease. TRIP12 has been shown to be involved in the regulation of inflammation by promoting the production of anti-inflammatory cytokines and by inhibiting the production of pro-inflammatory cytokines.

Biomarker Potential

TRIP12 has also been shown to be a potential biomarker for a number of diseases, including cancer, neurodegenerative diseases, and chronic kidney disease. One of the key reasons for its potential as a biomarker is its expression in a wide range of tissues and organs, including the brain, kidneys, and cancer cells. This makes it a potential marker for diseases that affect these organs, such as neurodegenerative diseases, cancer, and chronic kidney disease.

In addition, TRIP12 has been shown to be involved in the regulation of a wide range of cellular processes that are important for human health. This makes it a potential biomarker for a wide range of diseases, including those that are associated with inflammation, cell death, and cell growth.

Conclusion

In conclusion, TRIP12 is a ubiquitin-protein ligase that is expressed in the kidney and has been shown to play a role in a wide range of cellular processes that are important for human health. Its potential as a drug target and biomarker for various diseases makes it an attractive target for future research. Further studies are needed to fully understand the role of TRIP12 in human health and to develop effective treatments for diseases associated with its dysfunction.

Protein Name: Thyroid Hormone Receptor Interactor 12

Functions: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair (PubMed:19028681, PubMed:22884692). Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins (PubMed:19028681). Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes (PubMed:22884692). In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress (PubMed:20208519). In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation (PubMed:20208519). Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A (PubMed:20208519). Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation (PubMed:18627766). Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins (PubMed:20829358). Mediates ubiquitination of ASXL1: following binding to N(6)-methyladenosine methylated DNA, ASXL1 is ubiquitinated by TRIP12, leading to its degradation and subsequent inactivation of the PR-DUB complex (PubMed:30982744)

More Common Targets